- Home
- SERA
as 07-26-2024 4:00pm EST
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 258.3M | IPO Year: | 2021 |
| Target Price: | $2.75 | AVG Volume (30 days): | 331.9K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $12.36 | Next Earning Date: | 08-07-2024 |
| Revenue: | $206,000 | Revenue Growth: | -37.58% |
| Revenue Growth (this year): | 23.33% | Revenue Growth (next year): | 2400.00% |
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aerts Austin | SERA | Chief Financial Officer | Jun 10 '24 | Sell | $8.11 | 5,415 | $43,915.65 | 310,481 | SEC Form 4 |
| Kearney Paul | SERA | Chief Data Officer | May 15 '24 | Sell | $8.24 | 10,387 | $85,588.88 | 185,300 | SEC Form 4 |
| Aerts Austin | SERA | Chief Financial Officer | May 8 '24 | Sell | $9.59 | 6,592 | $63,217.28 | 315,896 | SEC Form 4 |
| Harrison Robert Gardner | SERA | Chief Information Officer | May 8 '24 | Sell | $9.59 | 4,902 | $47,010.18 | 140,795 | SEC Form 4 |
| Lindgardt Zhenya | SERA | Chief Executive Officer | May 8 '24 | Sell | $9.59 | 11,992 | $115,003.28 | 896,112 | SEC Form 4 |
| Kearney Paul | SERA | Chief Data Officer | May 8 '24 | Sell | $9.59 | 4,205 | $40,325.95 | 154,833 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | May 8 '24 | Sell | $9.59 | 4,902 | $47,010.18 | 134,869 | SEC Form 4 |
| Jackson Benjamin | SERA | General Counsel | May 8 '24 | Sell | $9.59 | 4,902 | $47,010.18 | 145,277 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 27 '24 | Sell | $9.62 | 3,753 | $36,103.86 | 139,771 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 27 '24 | Sell | $9.62 | 48,909 | $470,504.58 | 139,771 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 27 '24 | Sell | $9.04 | 24,474 | $221,244.96 | 139,771 | SEC Form 4 |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Mar 26 '24 | Sell | $9.37 | 38,899 | $364,483.63 | 908,104 | SEC Form 4 |
| Aerts Austin | SERA | Chief Financial Officer | Mar 26 '24 | Sell | $9.37 | 8,092 | $75,822.04 | 322,488 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 26 '24 | Sell | $9.55 | 21,438 | $204,732.90 | 143,524 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 25 '24 | Sell | $9.10 | 22,163 | $201,683.30 | 164,962 | SEC Form 4 |
| Harrison Robert Gardner | SERA | Chief Information Officer | Mar 6 '24 | Sell | $9.02 | 2,138 | $19,284.76 | 145,697 | SEC Form 4 |
| Aerts Austin | SERA | Chief Financial Officer | Mar 6 '24 | Sell | $9.02 | 444 | $4,004.88 | 330,580 | SEC Form 4 |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 6 '24 | Sell | $9.02 | 1,664 | $15,009.28 | 187,125 | SEC Form 4 |
| Kearney Paul | SERA | Chief Data Officer | Mar 6 '24 | Sell | $9.02 | 1,028 | $9,272.56 | 159,038 | SEC Form 4 |
| Jackson Benjamin | SERA | General Counsel | Mar 6 '24 | Sell | $9.02 | 1,856 | $16,741.12 | 150,179 | SEC Form 4 |
| Harrison Robert Gardner | SERA | Chief Information Officer | Feb 6 '24 | Sell | $8.03 | 5,665 | $45,489.95 | 147,835 | SEC Form 4 |
| Kearney Paul | SERA | Chief Data Officer | Feb 6 '24 | Sell | $8.03 | 4,984 | $40,021.52 | 160,066 | SEC Form 4 |
| Jackson Benjamin | SERA | General Counsel | Feb 6 '24 | Sell | $8.03 | 5,665 | $45,489.95 | 152,035 | SEC Form 4 |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Feb 6 '24 | Sell | $8.03 | 27,997 | $224,815.91 | 947,003 | SEC Form 4 |
| Aerts Austin | SERA | Chief Financial Officer | Feb 6 '24 | Sell | $8.03 | 9,786 | $78,581.58 | 331,024 | SEC Form 4 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
PR Newswire
17 days ago
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
MT Newswires
25 days ago
Sera Prognostics Joins Russell 2000, 3000 Indexes; Shares Rise
PR Newswire
25 days ago
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
Simply Wall St.
a month ago
Sera Prognostics, Inc. (NASDAQ:SERA) most popular amongst individual investors who own 31% of the shares, institutions hold 29%
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
Compare SERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.